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ABSTRACT 
The design and development of functional hybrid nanomaterials is currently a topic of 
great interest in biomedicine. Herein we investigated the grafting of Ru(II) polypyridyl 
complexes onto gold nanospheres (Ru@AuNPs) to improve the particles′ near infrared 
(NIR) absorption, and ultimately allow for application in photothermal cancer therapy. 
As demonstrated in this article, these ruthenium(II) complexes could indeed significantly 
enhance gold nanospheres’ two-photon luminescence (PTL) intensity and photothermal 
therapy (PTT) efficiency. The best dual functional nanoparticles of this study were 
successfully used for real-time luminescent imaging-guided PTT in live cancer cells. 
Furthermore, in vivo tumor ablation was achieved with excellent treatment efficacy under 
a diode laser (808 nm) irradiation at the power density of 0.8 W/cm2 for 5 min. This 
study demonstrates that the coupling of inert Ru(II) polypyridyl complexes to gold 
nanospheres allows for the enhancement of two-photon luminescence and for efficient 
photothermal effect. 
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1. Introduction 
Photothermal therapy (PTT) uses photon absorbers to convert optical energy into 
thermal energy to kill cancer cells. PTT has recently received extensive attention among 
researchers[1-11]. Gold nanoparticles are the most widely explored class of nanoagents 
due to their low toxicity and good biocompatibility. These properties make gold 
nanoparticles a promising platform for various biomedical applications, particularly for 
cancer diagnosis and treatment[12-14]. Over the past several years, gold nanorods[15] 
and nanoshells[16]-based near infrared (NIR) hyperthermia agents have been employed 
to photothermally kill cancer cells. However, gold nanorods have a low photostability 
since their NIR absorbance peak diminishes after a significant period of laser irradiation 
due to the “melting effect” [17]. Also, gold nanoshells are too large (diameter > 100 nm) 
for tissue accumulation and elimination[18]. 
Gold nanospheres (AuNPs) have significant advantages over other nanoparticles due 
to their small size, rapid synthesis and easy bioconjugation to various ligands such as 
DNA, peptides, antibodies and small guest molecules. These properties make them 
especially attractive as biological sensors[19,20]. However, the poor NIR absorbance of 
naked gold nanospheres limits their application in photothermal therapy[21,22]. It was 
recently demonstrated that aggregated gold nanospheres[23] and hollow gold 
nanospheres[24] can serve as agents for photothermal cancer therapy. However, the 
“melting effect” still occurs upon irradiation with a strong laser and the generated 
photothermal heat often melting hollow or anisotropic Au nanostructures into solid 
spheres, which indicates poor photothermal stability and thus easy loss of NIR surface 
plasmon resonance (SPR) properties. Herein, we propose a new strategy involving the 
adsorption of molecules with strong two-photon absorption onto the surface of AuNPs as 
antenna species to improve the particles’ NIR absorption, and ultimately allow for 
photothermal cancer therapy. 
Ru(II) polypyridyl complexes, owing to their more diverse stereochemistry than 
organic compounds, water-solubility, large Stokes shifts, good photostability and strong 
two-photon luminescence (TPL), have emerged as novel and promising candidates for 
biological probing and environmental monitoring[25-28]. To date, a few luminescent 
Ru(II) complex-functionalized AuNPs have been developed[29-33], and two examples of 
Ru(II)-functionalized AuNPs have been used for one-photon luminescent cellular 
imaging in living cells[31,33]. However, to the best of our knowledge, there is no report 
of the impact of Ru complexes on the efficiency of photothermal therapy or two-photon 
property of gold nanomaterials. More specifically, in this paper, we study: (1) how do the 
TPL and PTT of gold nanoparticles change after grafting terminal phenanthroline groups 
of Ru(II) complexes of various length (Fig. 1); (2) how does the size of these hybrid 
nanoparticles influence their PTT efficiency and TPL. The results showed that Ru(II) 
complexes can improve the AuNPs’ photothermal therapy efficiency and the two-photon 
luminescence in a significant manner. 
 
2. Materials and methods 
2.1. Materials and instruments 
Ruthenium chloride hydrate (Alfa Aesar, USA), bpy (2,2’-bipyridine, Sigma Aldrich, 
USA), MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoli-um bromide, Sigma 
Aldrich, USA), DMSO (dimethyl sulfoxide, Sigma Aldrich, USA), Rhodamine B 
(Sigma-Aldrich, USA) and DPBF (1,3-diphenyliso-benzofuran, Sigma Aldrich, USA) 
were used as received. Water with a resistivity of 18.2 MΩ·cm, which was used 
throughout the experiments, was purified with a Milli-Q system from the Millipore 
Company (USA). The complex [Ru(bpy)2(pdppz)]Cl2 (Ru2, bpy = 2,2'-bipyridine, pdppz 
= phenanthro[4,5-abc]dipyrido[3,2-h:2′, 3′-j]phenazine) was synthesised as previously 
described by our group[34]. 
Microanalysis (C, H, and N) were carried out on a Vario EL cube elemental analyzer. 
1H NMR spectra were recorded on a Varian INOVA500NB NMR spectrometer with 
(CD3)2SO as solvent at room temperature. All chemical shifts are given relative to 
tetramethylsilane (TMS). Electrospray ionization mass spectra (ESI-MS) were recorded 
on an LCQ system (Finnigan MAT, USA). The morphology and the microstructure of the 
Ru@AuNPs were characterized by transmission electron microscopy (TEM, 
JEM2010-HR, 200 KV), energy dispersive X-ray spectrometer (EDX, S-520/INCA 300, 
Japan) and field-emission scanning electron microscope (FE-SEM, JSM-6330F). The 
X-ray photoelectron spectroscopy (XPS, ESCALab250, Thermo VG) with 200 W Al KR 
radiation in twin anode. All core level XPS spectra were calibrated using C1s 
photoelectron peak at 284.6 eV as the reference. Dynamic light scattering and zeta 
potential experiments were determined by dynamic laser light scattering equipment (DLS, 
Brooken Haven BI-200SM). The average hydrodynamic diameter and the zeta potential 
of the Ru@AuNPs were measured 6 times for each solution, with the average of all the 
runs reported. UV-Vis-NIR spectra were recorded on a UV-3150 spectrophotometer 
(Shimadzu). Emission spectra were recorded on a PerkineElmer LS55 
spectrofluorophotometer at room temperature. A diode laser (808 nm) from Hi-Tech 
Optoelectronics Co., Ltd. (Beijing, China) and Xenon Light Source (450 nm, MAX-302, 
ASAHI Spectra, USA) were used in this study. 
 
2.2. Synthesis and characterization 
2.2.1. Synthesis of 2-diethoxymethyl-1H-imidazo[1,10]-phenanthroline (PIPOEt) 
To a solution of sodium ethoxide (0.6 g, 26.1 mmol of Na in 20 mL dry ethanol) were 
added 1,10-phenanthroline-5,6-diamine ( 2.7 g, 12.7 mmol) and ethyl diethoxyacetate 
(2.7 g, 15.1 mmol). The mixture was refluxed for 24 h, cooled to room temperature, and 
the solvent was removed under vacuum. The residue was dissolved in water, neutralized 
with acetic acid, and extracted with ethyl acetate. The combined organics were dried over 
anhydrous sodium sulfate, filtered, and evaporated to dryness. The residue was subjected 
to flash column chromatography (CHCl3/EtOAc = 2:1). Yield: 78%. 1H NMR (500 MHz, 
CDCl3-d6):  9.45 (d, J = 8.0 Hz, 2H), 9.18 (d, J = 8.5 Hz, 1H), 7.60 (dd, J = 8.5 Hz, 1H), 
5.48 (s, 1H), 3.49-3.70 (m, 4H), 1.26 (t, 6H, J = 8.0 Hz). ESI-MS (CH3OH) m/z: 323 
[M+H]+.  
 
2.2.2. Synthesis of 1H-imidazo[1,10]-phenanthroline-2-carbaldehyde (PIPCHO) 
Water (6 mL) and 37% hydrochloride acid (3 ml) were added to a THF (20 mL) 
solution of 2-diethoxymethyl-1H-imidazo[1,10]-phenanthroline (1.3 g, 4.0 mmol). After 
refluxing for 24 h, the reaction mixture was neutralized with saturated sodium 
bicarbonate and extracted with EtOAc (3  70 mL). The extract was washed with brine 
(2  50 mL), filtered, and evaporated to dryness. The residue was chromatographed on 
silica gel (Hexane/EtOAc 1:3). Yield: 78%. 1H NMR (500 MHz, CDCl3-d6):  10.35 (s, 
1H), 9.60 (d, J = 8.0 Hz, 2H), 9.34 (d, J = 7.5 Hz, 1H), 7.83 (dd, J = 8.0 Hz, 1H). 
ESI-MS (CH3OH) m/z: 248 [M+H]. 
 
2.2.3. Synthesis of [Ru(bpy)2(PIPCHO)](ClO4)2 
cis-[Ru(bpy)2Cl2]·2H2O (0.2 g, 0.4 mmol) and 1H-imidazo[1,10]-phenanthroline 
-2-carbaldehyde (0.1 g, 0.4 mmol) in ethanediol (10 mL) were heated to 125 ºC for 8 h 
under N2. The cooled reaction mixture was diluted with water (30 mL). Saturated 
aqueous sodium perchlorate solution was added under vigorous stirring and filtered. The 
dark red solid was collected and washed with small amounts of water, and diethyl ether, 
then dried under a vacuum and purified by column chromatography on alumina with 
acetonitrile-toluene (5:1 v/v) as the eluant. The solvent was removed under reduced 
pressure, and red microcrystals were obtained. Yield: 80%. Anal. Calcd for 
C34H24N8Cl2O9Ru (%): C, 47.45; H, 2.81; N, 13.02; Found (%): C, 47.34; H, 2.78; N, 
13.10. 1H NMR (500 MHz, DMSO-d6):  13.62 (s,1H, NH), 10.4 (s, 1H, CHO), 9.22 (d, 
J = 8.5 Hz, 2H), 8.87 (d, J = 8.0 Hz, 2H), 8.53 (m, 4H), 8.34 (d, J = 7.5 Hz, 2H), 8.11 (d, 
J = 8.0 Hz, 2H), 7.81 (m, 4H), 7.52 (t, J = 8.0 Hz, 4H), 7.19 (t, J = 7.5 Hz, 2H). ESI-MS 
(CH3OH) m/z: 331 [M2ClO4]2+, 662 [M2ClO4H]. 
 
2.2.4. Synthesis of [Ru(bpy)2(BPIP)]Cl2 (Ru1) 
9,10-phenanthrenequinone (0.1 g, 0.5 mmol), [Ru(bpy)2(PIPCHO)](ClO4)2 (0.42 g, 
0.5 mmol) and ammonium acetate (0.5 g, 6.0 mmol) in glacial acetic acid (10 mL) heated 
at 120 ºC for 4 h under an argon atmosphere. The solvent was removed under vacuum. 
The residue was then dissolved in water. The separated solid filtered and dried to give a 
red solid. The solid was then purified by column chromatography on alumina using 
acetonitrile-toluene (8:1 v/v) as the eluant. The complex was then converted to the 
chloride salt by dissolving the perchlorate complex in a minimum amount of acetone. 
This step is then followed by the slow addition of a saturated solution of 
tetrabutylammonium chloride in acetone. The chloride salt, which precipated, was 
filtered, washed with acetone and dried in vacuo. Yield: 85.1%. Anal. Calcd for 
C46H30N12Cl2O8Ru (%): C, 52.58; H, 2.88; N, 16.00; Found (%): C, 52.48; H, 2.79; N, 
16.12; 1H NMR (500 MHz, DMSO-d6):  13.68 (s, 1H, NH), 13.55 (s, 1H, NH) 9.11 (d, J 
= 8.0 Hz, 2H), 8.93 (d, J = 7.5 Hz, 2H), 8.84 (t, J = 8.5 Hz, 4H), 8.29 (d, J = 7.5 Hz, 4H), 
8.21 (t, J = 7.0 Hz, 4H), 8.10 (t, J = 7.5 Hz, 2H), 8.01 (m, 2H), 7.82 (d, J = 7.0 Hz, 2H), 
7.59 (dd, J = 8.0 Hz, 4H), 7.34 (t, J = 8.0 Hz, 2H). 13C NMR (126 MHz, DMSO-d6): 
163.11, 157.23, 156.99, 152.73, 152.48, 152.19, 151.90, 151.69, 146.88, 146.74, 145.04, 
138.61, 138.48, 136.16, 133.24, 131.64, 130.27, 128.42, 128.25, 127.57, 125.01, 124.75, 
121.24, 120.06. ESI-MS (CH3OH) m/z: 426 [M2Cl2]2+, 852 [M2Cl2H]. 
 
2.2.5. Synthesis of 2-(4-bromophenyl)-1H-imidazo[4,5-f][1,10]-phenanthroline (PIPBr) 
9,10-phenanthrenequinone (0.21 g, 1.0 mmol), 4-bromobenzaldehyde (0.185 g, 1.0 
mmol) and ammonium acetate (0.95 g, 12.2 mmol) in glacial acetic acid (10 mL) were 
heated for 4 h at 120 C, the cooled reaction mixture was neutralized with ammonia and 
then filtered off to give a pale yellow solid. The solid was recrystallized in ethanol. Yield: 
80.5%. Anal. Calcd for C19H11BrN4：C, 60.82; H, 2.95; N, 14.93; Found: C, 60.91; H, 
2.87; N, 14.80. 1H NMR (500 MHz, CDCl3-d6):  8.93 (d, J = 8.3 Hz, 2H), 8.54 (d, J = 
8.5 Hz, 2H), 7.82 (t, J = 8.4 Hz, 2H), 7.75 (d, J = 7.8 Hz, 2H), 7.62 (m, J = 8.0 Hz, 2H). 
ESI-MS (CH3OH) m/z: 376 [M+H]. 
 
2.2.6. Synthesis of [Ru(bpy)2(PIPBr)](ClO4)2 
cis-[Ru(bpy)2Cl2]·2H2O (0.2 g, 0.4 mmol) and PIPBr (0.15 g, 0.4 mmol) in 
ethanediol (10 mL) were heated to 125 ºC for 8 h under N2. The cooled reaction mixture 
was then diluted with water (30 mL). Saturated aqueous sodium perchlorate solution was 
added under vigorous stirring and the precipitate filtered. The dark red solid was 
collected and washed with small amounts of water and diethyl ether. It was then dried 
under vacuum and purified by column chromatography on alumina using 
acetonitrile-toluene (3:1 v/v) as the eluant to obtain red microcrystals. Yield: 85.1%. Anal. 
Calcd for C39H27N8BrCl2O8Ru (%): C, 47.43; H, 2.76; N, 11.35; Found (%): C, 47.61; H, 
2.61; N, 11.46. 1H NMR (500 MHz, DMSO-d6):  9.03 (d, J = 8.0 Hz, 2H), 8.83 (dd, J = 
8.0 Hz, 4H), 8.22 (m, 4H), 8.08 (t, J = 8.5 Hz, 2H), 7.97 (d, J = 8.0 Hz, 2H), 7.82 (d, J = 
8.5 Hz, 4H), 7.56 (t, J = 8.5 Hz, 4H), 7.32 (t, J = 7.5 Hz, 2H), 7.18 (m, 2H). ESI-MS 
(CH3OH) m/z: 394 [M2ClO4]2+, 788 [M2ClO4H].  
 
2.2.7. Synthesis of [Ru(bpy)2(PIPBCHO)](ClO4)2 
A solution of [Ru(bpy)2(PIPBr)](ClO4)2 (0.99 g, 1.0 mmol), 
4-(diphenylamino)phenylboronic acid (0.37 g, 1.6 mmol), Pd(PPh3)4 (0.061 g, 0.053 
mmol), and aqueous Na2CO3 (2 M, 4 mL) in toluene (8 mL) and ethanol (3 mL) were 
heated to reflux under an argon atmosphere for 24 h. The solution was cooled to room 
temperature and concentrated by rotary evaporation. Water was added under vigorous 
stirring and the precipitate filtered off. The residue was purified by column 
chromatography on alumina using acetonitrile-toluene (10:1 v/v) as the eluant. Yield: 
72.1%. Anal. Calcd for C46H32N8Cl2O9Ru (%): C, 54.55; H, 3.18; N, 11.06; Found (%): 
C, 54.41; H, 3.31; N, 11.30. 1H NMR (500 MHz, DMSO-d6): 13.6 (s, 1H), 10.2 (s, 1H), 
9.15 (d, J = 8.0 Hz, 2H), 9.02 (d, J = 8.5 Hz, 4H), 8.86 (d, J = 7.5 Hz, 4H), 8.28 (m, 4H), 
8.02 (t, J = 8.5 Hz, 2H), 7.83 (dd, J = 8.0 Hz, 4H), 7.67 (dd, J = 8.0 Hz, 4H), 7.50 (m, 
4H), 7.38 (t, J = 7.5 Hz, 2H). ESI-MS (CH3OH) m/z: 407 [M2ClO4]2+, 813 
[M2ClO4H]. 
 
2.2.8. Synthesis of [Ru(bpy)2(PIPBP)]Cl2 (Ru3) 
9,10-phenanthrenequinone (0.1 g, 0.5 mmol), [Ru(bpy)2(PIPBCHO)](ClO4)2 (0.51 g, 
0.5 mmol) and ammonium acetate (0.5 g, 6.0 mmol) in glacial acetic acid (10 mL) heated 
at 120 ºC for 4 h under an argon atmosphere. The solvent was removed under vacuum. 
The residue was then dissolved in water. The separated solid was filtered off and dried to 
give a red solid. The solid was purified by column chromatography on alumina with 
acetonitrile-methanol (10:1 v/v) as the eluant. The complex was then converted to the 
chloride salt by dissolving the perchlorate complex in a minimum amount of acetone, 
followed by the slow addition of a saturated solution of tetrabutylammonium chloride in 
acetone. The chloride salt was filtered off, washed with acetone and dried. Yield: 72.1%. 
Anal. Calcd for C58H38N12Cl2O8Ru (%): C, 57.91; H, 3.18; N, 13.97; Found (%): C, 
57.71; H, 3.14; N, 13.72. 1H NMR (500 MHz, DMSO-d6):  13.68 (s, 1H, NH), 13.60 (s, 
1H, NH), 8.35 (d, J = 8.5 Hz, 4H), 8.11 (t, J = 8.0 Hz, 6H), 7.57 (d, J = 7.5 Hz, 2H), 7.48 
(dd, J = 8.5 Hz, 4H), 7.33 (m, 5H), 7.17 (t, J = 8.0 Hz, 3H), 7.08 (d, J = 7.5 Hz, 2H), 
6.85 (m, 8H), 6.59 (t, J = 8.5 Hz, 2H). 13C NMR (126 MHz, DMSO-d6):  157.26, 
157.05, 155.43, 155.37, 153.33, 152.76, 151.95, 151.87, 150.32, 147.81, 145.51, 144.13, 
138.44, 138.28, 132.72, 132.52, 132.00, 131.92, 130.92, 130.87, 130.06, 129.74, 129.29, 
129.19, 128.91, 128.37, 128.23, 127.09, 126.81, 125.72, 124.94, 124.85. ESI-MS 
(CH3OH) m/z: 502 [M2Cl2]2+, 1004 [M2Cl2H]. 
 
2.2.9. Synthesis of the Ru@AuNPs 
The phase transfer was realized by a modification of the Brust two-phase synthesis. 
HAuCl4·3H2O (3.87 mg, 10 mol) was first solubilized in water (1 mL) and was then 
transferred to the toluene (2 mL) phase using tetraoctylammoniumbromide (9 mg, 16.5 
mol) as the phase-transfer agent. NaBH4 in water (0.1 mol L−1-sample A, 0.2 mol 
L−1-sample B, 0.4 mol L−1-sample C, 0.8 mol L−1- sample D) was then added at once to 
the previous toluene solution. The resulting mixture was then stirred for 1 h. The three 
complexes Ru1, Ru2, Ru3 (4.93 mol) in water (10 mL) were finally added and the 
resulting mixture was stirred for 1 h. The initial orange aqueous solution turned to dark 
brown confirming the phase transfer of the the Ru@AuNPs from toluene to the aqueous 
solution. A dialysis procedure was used to remove the unreacted reagents with 3500 
molecular weight cutoff dialysis membrane. The nanoparticles were then centrifuged at 
15000 rpm for 1 h. 
 
2.3. Determination of two-photon absorption cross sections 
The two-photon absorption spectra of the probes were determined over a broad 
spectral region by the typical two-photon induced fluorescence (TPF) method relative to 
Rhodamine B in methanol as the standard[35]. The two-photon fluorescence data were 
acquired using an OpoletteTM 355II (pulse width ≤ 100 fs, 80 MHz repetition rate, 808 
nm, Spectra Physics Inc., USA). Two-photon fluorescence measurements were 
performed in fluorometric quartz cuvettes with the Ru complex/Ru@AuNPs in water. 
The experimental fluorescence excitation and detection conditions were conducted with 
negligible re-absorption processes, which can affect TPA measurements. The quadratic 
dependence of two-photon induced fluorescence intensity on the excitation power was 
verified at an excitation wavelength of 808 nm. The two-photon absorption cross section 
of the probes was calculated at each wavelength according to equation[35]. 
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where I is the integrated fluorescence intensity, C is the concentration, n is the refractive 
index, and  is the quantum yield. Subscript ‘1’ stands for reference samples, and ‘2’ 
stands for samples. 
 
2.4. Deterimination of the number of Ru molecules per gold nanoparticle 
The Ru@AuNPs were completely digested by 5 mL of aqua regia at 50 ºC. The 
solution was evaporated to 0.5 mL and cooled down to room temperature. Subsequently, 
the sample was diluted to 3% HNO3 with Milli Q H2O, and then analyzed by inductively 
coupled plasma mass spectrometry (ICP-MS, Thermo Elemental Co., Ltd.). 
Quantification was carried out by external five-point calibration. The number of Ru 
molecules per gold nanoparticle is calculated as follows[36]: 
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m: measured density of ions (atoms) from ICP/MS analysis (g/L) 
: density of Au 
: the radius of naked AuNPs 
n: molar number 
M: molecular weight (g/mol) 
R: atomic percentage of Ru to AuNPs 
 
2.5. Photothermal effect measurements 
For photothermal measurements, 100 L of the Ru@Au nanoparticles solutions at the 
same concentration (50 g/mL) was placed in a series of specimen cuvettes and each 
cuvette was irradiated by an 808 nm laser (0.8 W/cm2, 5 min). Light-induced temperature 
change in the solutions was collected by using a thermal camera (MAG30, Magnity 
Electronics, Thermal Imaging Expert). Pure AuNPs were measured as the control groups, 
and a total of three replicates were conducted for each sample. The photothermal 
conversion efficiency of Ru@AuNPs was determined according to the method[37].   
 
2.6. Singlet oxygen detection 
Singlet oxygen sensor (DPBF), that is highly selective for singlet oxygen, was used to 
evaluate the singlet oxygen generation (SOG) of the Ru2@AuNPs. The concentration of 
the Ru2@AuNPs was fixed a 50 g/mL. The mixture solutions were irradiated with an 
808 nm laser (0.8 W/cm2) or a 450 nm Xenon lamp at different irradiation times. DPBF 
was dissolved in water containing 2% methanol with a final concentration of 10 M. 
DPBF fluorescence emission was produced using an excitation wavelength of 405 nm. 
The fluorescence intensity at 479 nm was recorded as a function of irradiation time. The 
sample’s SOG was evaluated by the DPBF fluorescence enhancement compared with the 
background or control samples.  
The 1O2 generation quantum yield (Δ) was calculated according to Eqs.(6) and (7), 
where Iin is the incident monochromatic light intensity, Φab is the light absorbing 
efficiency, Φr is the reaction quantum yield of 1O2 with DPBF 
(1,3-diphenyl-isobenzofuran), t is the reaction time, I0 and It are the fluorescence 
intensities of DPBF by the addition of Ru2@AuNPs before and after irradiation, k is the 
slope of plots (the curve of the DPBF consumption percentage at 479 nm as a function of 
irradiation time) and superscript s stands for standard[38]. The standard was [Ru(bpy)3]2+ 
(ΦsΔ = 0.81)[39]. 
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2.7. Reactive oxidative species (ROS) measurement[40-42]  
The production of intracellular ROS was detected by 2′, 7′-dichlorofluorescin diacetate 
(H2DCF-DA, Sigma-Aldrich), a cell-permeable nonfluorescent probe which is 
deesterified in cell and upon oxidation turns to highlyfluorescent 2′, 7′-dichlorofluorescin. 
HeLa cells were seeded in white 96-well plates at a density of 1×104 cells one day before 
treatment. The medium was removed and H2DCF-DA (10 M) was added to cells for 30 
min at 37°C in the dark. The cells were subsequently washed in serum-free medium and 
treated for 30 min, 2 h, 4 h, or 8 h with Ru2@AuNPs (50 g/mL), then irradiated 5 min 
by a diode laser (808 nm, 0.8 W/cm2) or a Xenon lamp (450 nm, 100 mW) in the absence 
or the presence of 10 mM N-acetylcysteine (NAC, an antioxidant, Alfa Aesar). 
Fluorescence was quantified at 530 nm emission with 488 nm excitation wavelength 
using a microplate reader (Infinite M200 Pro, Tecan, Männedorf, Switzerland). 
 
2.8. Cell cultures and cytotoxicity test 
Human cervical carcinoma cancer cell lines (HeLa) were obtained from the Center for 
Experimental Animals, Sun Yat-Sen University (Guangzhou, China). All cell lines were 
maintained in DMEM media, which supplemented with 100 U/ml penicillin. 
1×104 cells/well were seeded in a 96-well flat bottomed multi-well plate with 
supplemented culture medium (100 L/well) followed by incubation with 5% CO2/95% 
air at 37 ºC for 24 h. After adding the serially diluted solutions of the Ru2@AuNPs, the 
cells were incubated with 5% CO2/95% air at 37 ºC for 12 h. The cells were then exposed 
to a diode laser (808 nm) for 5 min. The irradiated plates were returned to the incubator 
for another 12 h. Cell viability was measured with the MTT assay. The optical density of 
each well was then measured using a microplate spectrophotometer at a wavelength of 
590 nm. All cytotoxicity tests were performed in parallel with negative control, which 
consisted of cells in the presence of the drugs without irradiation. 
 
2.9. Calcein AM staining 
Live cells were distinguished by the presence of ubiquitous intracellular esterase 
activity, as determined by the enzymatic conversion of the virtually nonfluorescent 
cell-permeant calcein AM to the intensely fluorescent calcein (λex = 488 nm, λem = 520  
20 nm). The determination of cell viability depends on these physical and biochemical 
cell properties[43]. After cancer cells treatment with the Ru2@AuNPs (50 g/mL) and a 
diode laser (808 nm) irradiation (0.8 W/cm2, 5 min), and the control cells in the presence 
of the Ru2@AuNPs without irradiation, the cancer cells were incubated with calcein AM 
(2 M) solutions for 30 min and imaged directly using an inverted fluorescence 
microscope (Zeiss Axio Observer D1, Germany). 
 
2.10. Two-photon luminescence imaging  
HeLa cell lines were incubated with the Ru2@AuNPs (50 g/mL) for 1 h at 37 ºC. 
After being washed with fresh PBS (pH = 7.0) three times, the cells under real time 
irradiation were imaged on a Zeiss LSM 710 NLO confocal microscope (63 oil 
immersion objective). The excitation wavelength of the laser was 808 nm, and the 
two-photon images were integrated over the range of 580-650 nm.  
 
2.11. Cell uptaken analysis  
Flow Cytometry Analysis. HeLa cells at a density of 1105 cells/mL were cultured in 
6-well plates for 24 h in an incubator, and then Ru2@AuNPs was added with fresh 
DMEM, which were followed by further incubation for 0.5 h and 1 h, respectively. Then, 
the cells were trypsinised and washed with PBS. The cell uptake samples were analysed 
by a FACSCanto II (BD Biosciences, USA). 
ICP-MS analysis. Exponentially grown HeLa cells were plated at a density of 1×104 
cells per mL in a volume of 5 mL of DMEM medium. The Ru2@AuNPs were added to 
the culture medium (final DMSO concentration less than 0.1% v/v) and incubated for 
varying amounts of time at 37 °C. After digestion by a trypsin-EDTA solution, the HeLa 
cells were counted and divided into three portions. In the first portion, the nuclei were 
extracted using a nucleus extraction kit (Shanghai Sangon Biological Engineering 
Technology & Services Co. Ltd.); in the second portion, the cytoplasm was extracted 
using a cytoplasm extraction kit (Shanghai Sangon Biological Engineering Technology 
& Services Co. Ltd.); and in the third portion, the whole cell was used. The samples were 
digested with 60% HNO3 at room temperature for one day. Each sample was diluted with 
MilliQ H2O to obtain 3% HNO3 sample solutions. The standards for calibration were 
freshly prepared by diluting these stock solutions with 3% HNO3 in MilliQ H2O. The 
ruthenium concentrations in the three portions were determined using inductively 
coupled plasma mass spectrometry (ICP-MS Thermo Elemental Co., Ltd.). 
TEM analysis. HeLa cells (5  105) were treated with the Ru2@AuNPs (50 g/mL) at 
37 ºC for 1 h. The cells were washed twice and fixed with 2% glutaraldehyde at 4 ºC for 
1 h. The cells were then dehydrated with sequential washes in ethanol and embedded in 
Spurr’s resin. The obtained ultrathin sections were mounted in copper grids, 
counterstained with uranyl acetate and lead citrate, and visualized in an electron 
microscope (TEM 100 CX, JEOL, Tokyo, Japan). 
 
2.12. Photothermal therapy in vivo 
Balb/c-(nu/nu) female nude mice aged 4 to 5 weeks were purchased and bred in the 
Center of Experiment Animal of Sun Yat-sen University. All experimental protocols were 
approved by the Sun Yat-sen University Animal Care and Use Committee. HeLa 
xenografts were established by inoculating 2 × 106 cells via subcutaneous injection (s.c.) 
into BALB/c-(nu/nu) female nude mice. When the tumor volume reached approximately 
120 mm3, the nude mice were randomly allocated into six groups (8 mice per group) 
before the experiments.  
Photothermal therapy process was as followed. Group 1 (Ru2@AuNPs): mice were 
intratumorally injected with the Ru2@AuNPs (40 L/20 g body weight of 5 mg/mL 
solution, a dose of 200 g Ru2@AuNPs/20 g body weight); Group 2 (Ru2@AuNPs + 
laser): mice were intratumorally injected with the Ru2@AuNPs (40 L/20 g body weight 
of 5 mg/mL solution, 200 g Ru2@AuNPs/20 g body weight); Group 3 (AuNPs + laser): 
mice were intratumorally injected with the AuNPs (40 L/20 g body weight of 5 mg/mL 
solution, a dose of 200 g AuNPs/20 g body weight). Group 4 (Ru2 + laser): mice were 
intratumorally injected with the Ru2 (40 L/20 g body weight of 5 mg/mL solution, a 
dose of 200 g Ru2/20 g body weight). Group 5 (physiological saline): mice were 
intratumorally injected with the same volume of physiological saline solution; Group 6 
(physiological saline + laser): mice were intratumorally injected with the same volume of 
physiological saline solution. After the injection, each mouse of group 2, group 3, group 4, 
and group 6 was irradiated with a diode laser (808 nm, Hi-Tech Optoelectronics Co., Ltd. 
Beijing, China) at 0.8 W/cm2 for 5 min. Group 1 and group 5 (without laser irradiation) 
were used as the controls.  
After the irradiation (day 0), the tumor sizes were measured using a caliper every 2 days. 
The mice with tumors were photographed with a digital color camera at day 0 and day 10. 
The tumor volumes were calculated based on the following formula: Tumor Volume (V) = 
(tumor length)  (tumor width)2/2. Relative tumor volumes were calculated as V/V0 (V0 
was the initial tumor volume of Day 0)[44,45]. 
 
2.13. Histological examination 
At the end of the photothermal therapy in vivo, all the mice of the five groups were 
sacrificed and the organs including liver, kidney, spleen, heart, lung, brain, intestine, ovary 
and tumor tissue were resected. A portion of these fresh tissues were immersed in 4% 
paraformaldehyde at 4 °C. For morphological studies, 6 μm sections were obtained from 
paraffin-embedded samples, processed according to the standard procedures for inclusion, 
and rehydrated (xylene, alcohol, water). Sections were stained with hematoxylin-eosin 
(H&E), Hematoxylin has a deep blue-purple color and stains nucleic acids. Eosin is pink 
and stains proteins nonspecifically. In a typical tissue, nuclei are stained blue, whereas the 
cytoplasm and extracellular matrix have varying degrees of pink staining. The sections 
were observed with an Olympus microscope to analyze the tissue structure and cell state. 
 
2.14. Statistical analysis 
Data were presented as mean ± standard deviation, and significance was assessed with 
Student’s t test. Differences were considered significant at P < 0.05. 
 
3. Results and discussion 
3.1. Design and synthesis 
The synthesis and characterization of the phenanthroline ligands of three different 
length chelating the ruthenium centre are presented in the Supporting Information 
(Schemes S1-S2 and Fig. S1-S6). The Ru@AuNPs were synthesized based on the 
two-phase method developed by Mayer et al[30]. The lone electron pairs of the nitrogen 
atoms in the phenantroline ligand have a strong affinity to the gold surface and form 
stable and water-soluble Ru@AuNPs. TEM studies showed that the Ru@AuNPs were 
highly monodisperse, unaggregated and spherical in shape (Fig. 2a, b and Fig. S7). 
Solutions of the Ru@AuNPs were stable at room temperature for a period of 3 months 
(Fig. S8). The size of the Ru@AuNPs is increased when the molar ratio of the reducing 
agent (NaBH4) is increased (Table 1). The formation of the Ru@AuNPs upon variation 
of the ratio of NaBH4, was followed by UV-Vis spectroscopy (Fig. S9). While the two 
bands of the Ru(II) complex was observed at 365 nm and 458 nm, respectively, the 
surface plasmon resonance (SPR) band of the citrate-AuNPs was located at 520 nm, 
whereas the SPR band of the Ru@AuNPs was red shifted to 570 nm. This indicates the 
formation of N-Au bonds between the Ru(II) complex and the AuNPs. Moreover, the 
Ru@AuNPs exhibit stronger broad NIR absorption than the Ru(II) complex and the 
AuNPs themselves. This trait forms the foundation of the particles’ photothermal effects. 
The elements contained in the Ru2@AuNPs were further determined via energy 
dispersive X-ray spectroscopy analysis (EDX) and X-ray photoelectron spectroscopy 
(XPS) measurements (Fig. 2c-d, Fig. S10 and Table S1). The results provided the 
chemical composition and the energy distribution of Au4f, Ru3d, C1s, O1s and N1s, which 
indicated that the Ru complex was modified onto the AuNPs surface. 
The number of Ru molecules per gold nanoparticle was determined via ICP-MS, after 
digestion of the AuNPs in aqua regia. The calculation method is detailed in the 
Supporting Information. The results revealed that there were more than one hundred 
Ru(II) complexes per gold nanoparticle, which is a greater number than that observed for 
analogous systems[46,47]. As anticipated, for the same Ru(II) complex, the larger the 
nanoparticles are, the more Ru complexes per gold nanoparticle are present. In addition, 
the longer the spacer between the Ru(II) complex and the gold nanoparticle is, the more 
Ru complexes are present at the surface of the AuNPs. This is most likely due to a higher 
steric hindrance on the surface of gold nanoparticles. The Zeta potential of all 
Ru@AuNPs is positive and increases upon the number of Ru complexes present due to 
their positive charges (Table 1). 
 
3.2. Photophysical properties of the Ru@AuNPs 
We then investigated the luminescence of the Ru@AuNPs. To some extent, the 
luminescence of the Ru(II) complex was partly quenched due to an energy transfer from 
the Ru(II) complex to the AuNPs (Fig. S11 and Table 1). The quenching process is 
related to various factors such as the size of the nanoparticles or the distance between the 
AuNPs and the ruthenium complexes. For the same Ru(II) complex, the results show that 
the large gold nanoparticles have a higher quenching efficiency than the small 
nanoparticles. For the same size nanoparticles (45 nm of Ru1@AuNPs, Ru2@AuNPs 
and Ru3@AuNPs), the longer the distance between photosensitiser and quencher is, the 
lower the quenching efficiency is (96.5% quenching for the Ru1@AuNPs vs. the free 
Ru1 complex, 57.9% quenching for the Ru2@AuNPs vs. the free Ru2 complex, and 40.5% 
quenching for the Ru3@AuNPs vs. the free Ru3 complex). 
Next, the two-photon luminescence (TPL) properties of the Ru@AuNPs were 
investigated by determining the two-photon absorption cross-section  (TPA) of the 
Ru@AuNPs using rhodamine B as a reference (Table 1 and Fig. 3). As expected, the 
AuNPs alone displayed almost no TPL. However, the Ru2@AuNPs and the 
Ru3@AuNPs exhibit strong two-photon emission upon 808 nm excitation. The 
Ru2@AuNPs have the largest TPA (808nm = 187–308 Göppert–Mayer (GM); 1 GM = 1  
10-50 cm4s-1photon-1) since Ru2 complex has the strongest two-photon luminescence 
(808nm = 394 GM). However, the Ru1@AuNPs exhibited the smallest TPA (808nm = 
7.8–18 GM) of the series due to the strongest quenching efficiency. The two-photon 
excitation active process was confirmed via a power dependence experiment. A log-log 
linear relationship between the emission intensity and incident power showed the best-fit 
with a gradient (n  2) (Fig. S12). The nanoparticles’ size also influenced their TPL 
intensity. For the same Ru(II) complex coated on the AuNPs, the two-photon 
luminescence decreased upon increase of the particles’ size. In other words, the TPL 
intensity of the Ru@AuNPs is stronger than the AuNPs themselves (no TPL) because the 
two-photon luminescence of the Ru(II) complexes is transferred to the AuNPs. The TPL 
of the Ru@AuNPs mainly depends on the TPL of Ru(II) complexes, the distance 
between the Ru(II) complexes and the AuNPs, and the size of the Ru@AuNPs. 
 
3.3. Photothermal properties of the Ru@AuNPs 
We then investigated the photothermal therapy potential of our nanoparticles. For this 
purpose, we used a diode laser (808 nm) at a power density of 0.8 W/cm2 to irradiate 
water, pure gold nanoparticles and the Ru@Au nanoparticles (45.01.5 nm size, 100 L, 
50 g/mL) for different irradiation times (0-5 min). We then used a thermal imaging 
camera to record the temperature variation (Fig. 4). The thermal signals of pure water 
show no obvious change (ΔT  2 C). The AuNPs were shown to convert NIR light to 
heat (ΔT = 8.612.5 C; sample D in Table 1: 12.5 C). However, these temperature 
increases (ΔT) were much lower than those observed for the Ru@AuNPs (ΔT = 
19.438.5 C; sample D in Table 1: 38.5 C) in the same experimental conditions. 
Moreover, the photothermal conversion efficiency () of all Ru@AuNPs were higher 
than this of the AuNPs ( = 7.3%10.2% for AuNPs and  = 18.3%33.3% for the 
Ru@AuNPs). Some of them are markedly higher than those of gold nanorods (22%), 
gold nanoshells (13%), gold nanocages (18%) and gold nanostars (17.9%)[48,49]. In 
agreement with the fact that Ru2 complex had the highest TPL of the complexes studies 
in this work, the Ru2@AuNPs were found to have the highest temperature increase. 
Concurrently, the Ru3@AuNPs exhibited a minimum temperature increase since 
complex Ru3 had the weakest TPL of the series of complexes examined in this study. In 
addition, since complex Ru3 has the longest spacer, this results onto a low energy 
transfer to the AuNPs. When the Ru2@AuNPs concentration (sample D in Table 1) was 
fixed at 50 g/mL, an obvious power density dependent temperature rise was observed 
(Fig. S13). A temperature increase to 50 C can be obtained with an incident laser 
power as low as 0.5 W/cm2. This temperature increase is well above the required 
temperature rise for efficient cancer photothermal therapy[50]. In addition, T was found 
to increase more significantly when larger Ru@AuNPs were investigated since larger 
Ru@AuNPs have higher NIR absorption (Fig. S14). All in all, these results clearly show 
that the grafting of Ru(II) complexes with strong TPL onto AuNPs can significantly 
enhance the AuNPs’ photothermal therapy efficiency. 
The photothermal stability of the Ru2@AuNPs was further examined and 
benchmarked against Au nanorods (AuNRs) by exposing the NPs under a diode laser 
(808 nm) irradiation at the power density of 0.8 W/cm2, with their near-infrared 
absorption spectra and the corresponding TEM images taken before and after 30 min of 
laser illumination (Fig. 5). The NIR SPR absorption of the AuNRs blue-shifted and 
decreased in intensity after laser exposure, indicating morphological changes to solid 
spheres due to the “melting effect”[51,52]. The latter was also confirmed by TEM 
images, showing large spherical Au particle formation after being exposed to laser 
irradiation. On the contrary, no significant change in the solution absorbance or 
nanostructure morphology of the Ru2@AuNPs was observed under the same 
experimental conditions. This clearly indicates the high photothermal stability of our 
Ru2@AuNPs. Moreover, the Ru2@AuNPs were able to generate heat after repetitive 
laser exposure (Fig. S15). The laser ON-OFF cycle was repeated five times to investigate 
the photothermal conversion stability of the Ru2@AuNPs. Ru2@AuNPs were irradiated 
with a NIR laser for 5 min (Laser ON), followed by naturally cooling to room 
temperature without NIR laser irradiation over a period of 20 min (Laser OFF). No 
distinct change in the rise in temperature is observed for Ru2@AuNPs after five laser 
ON/OFF cycles. 
In addition, to determine whether the Ru2@AuNPs can produce singlet oxygen (1O2) 
upon light irradiation, we performed experiments to detect the potential formation of 1O2. 
Indeed, it is well-known that certain inert polypyridyl ruthenium complexes can produce 
1O2 upon irradiation in the UV-Vis region[40-42]. As expected, using a singlet oxygen 
sensor (DPBF)[38], we found out that the Ru2@AuNPs were producing 1O2 upon Xenon 
lamp (450 nm, 100 mW) irradiation (Fig. S16a). Using [Ru(bpy)3]2+ as standard (ΦΔ = 
0.81) [39], the 1O2 generation quantum yield ΦΔ of Ru2@AuNPs was determined to be 
0.20 upon 450 nm Xenon lamp irradiation in water. However, the irradiation of the 
Ru2@AuNPs with a diode laser (808 nm) at a power density of 0.8 W/cm2 did not 
produce any singlet oxygen (Fig. S16b). The 808 nm diode laser may be not strong 
enough to produce 1O2. We also considered whether the Ru2@AuNPs could produce 
other reactive oxidative species (ROS) than 1O2 upon 808 nm laser irradiation. 
H2DCF-DA (2′,7′-dichlorofluorescin diacetate) has been widely used to assess the 
production of ROS in living cells[42]. Using this dye, we could show that ROS were not 
produced in HeLa cells when the Ru2@AuNPs were irradiated for 5 min with a diode 
laser (808 nm) at a power density of 0.8 W/cm2 (Fig. S17a). However, when the 
Ru2@AuNPs (50 g/mL) were irradiated for 5 min with a Xenon lamp (450 nm, 100 
mW), ROS was detected (Fig. S17b). These observations emphasize that the production 
of ROS is linked to the irradiation wavelength. 
 
3.4. In vitro photothermal cell ablation 
After having fully characterised the Ru@AuNPs, we examined the viability of HeLa 
cells treated with the Ru2@AuNPs (45.01.5 nm size, 50 g/mL) without irradiation and 
upon 5 min laser irradiation (808 nm, 0.8 W/cm2). The Ru2@AuNPs exhibited almost no 
cytotoxicity without irradiation (Fig. 6a). HeLa cells also exhibited no loss of viability 
after being irradiated in the absence of the nanoparticles (Fig. 6b). It means that the 
untreated cells remain unaffected under these laser irradiation powers (from 0.3 W/cm2 
to 1 W/cm2). However, cells exposed to the Ru2@AuNPs and then irradiated, exhibited a 
dramatically reduced cell viability. The results indicated that the Ru2@AuNPs have a 
great PPT effect in living cells contrary to AuNPs, which only displayed a weak PTT 
effect[21-22]. Considering the red luminescence of the Ru2@AuNPs, the PPT effect of 
the Ru2@AuNPs was then monitored via calcein AM staining assay (Fig. S18). Viable 
cells were stained green with calcein AM. HeLa cells treated with the Ru2@AuNPs (50 
g/mL) followed by 808 nm laser irradiation (0.8 W/cm2 for 5 min) died (representing by 
the significant reduction of green fluorescence). All other groups (control, laser alone and 
Ru2@AuNPs alone) showed no observable damage to the cancer cells. In addition, to 
make sure that the cytotoxicity observed was not due to the Ru complexes themselves, 
we investigated the intrinsic cytotoxicity of the Ru complexes (Ru1-3) to HeLa cell lines 
using a MTT assay. The Ru(II) complexes also did not exhibit any obvious cytotoxicity 
towards the HeLa cells after 24 h incubation (Fig. S19). 
With these results in hand, we concluded that the Ru2@AuNPs (45.01.5 nm size, 
sample D) not only have the strongest heat treatment, but also have the strongest 
two-photon luminescence of all nanoparticles investigated in this study. Thus, the 
two-photon luminescent imaging-guided PTT of the Ru2@AuNPs was examined (Fig. 
6c). Red two-photon luminescence was observed in the cell membrane and the cytoplasm 
upon light irradiation with an 808 nm laser (0.8 W/cm2). Furthermore, ballooning bulges 
were observed (green arrow) after irradiation for 1 min and 2 min at 808 nm. Not only 
did a necrotic apoptotic body area form (yellow arrow) after a 5 min irradiation, but the 
viability of cells around the circular NIR-irradiated region was also compromised. These 
results demonstrate the excellent potential of the Ru2@AuNPs as photothermal therapy 
agents against HeLa cancer cells. 
 
3.5. Cell uptake analysis 
In order to understand in more detail the mode of action of the Ru2@AuNPs, the 
cellular uptake and localization of the Ru2@AuNPs were examined in HeLa cells. Flow 
cytometry was used to obtain qualitative data regarding Ru2@AuNPs uptake into HeLa 
cells. The luminescence intensity of the cell population increased significantly after 
incubating with the Ru2@AuNPs (Fig. 7a). Quantitative analysis (ICP-MS) provided 
absolute values for the cellular uptake of the Ru2@AuNPs (Fig. 7b). The results revealed 
that the Ru2@AuNPs mainly go to the cytoplasm and to a much smaller extend to the 
nucleus. The subcellular localization of the Ru2@AuNPs was further confirmed via 
confocal fluorescence microscopy (Fig. 7c). The red two-photon luminescence mainly 
accumulated in the cytoplasm. TEM is a convincing method for observing the pathways 
through which the Ru2@AuNPs enter cancer cells. This tecnhnique supports an 
endocytosis mechanism for the uptake of the Ru2@AuNPs and shows that the 
Ru2@AuNPs form endosomes in cells (Fig. 7d). 
 3.6. Photothermal therapy in vivo 
We further attempted to study the in vivo photothermal therapy efficacy of our 
Ru2@AuNPs. At this stage, it should be pointed out that the preferred route of 
photothermal conversion agents (PTCAs) administration in photothermal cancer therapy 
is intratumoral injection instead of intravenous injection[53-56]. Nie et al. recently 
reported that active molecular targeting of the tumor microenvironments (e.g., fibroblasts, 
macrophages, and vasculatures) did not significantly influence the tumor nanoparticle 
uptake when the gold nanoparticels were administered via intravenous injection[57]. 
Because of this, we opted in the present study for intratumoral injection to assesss the in 
vivo PPT potential of our Ru2@AuNPs. 
In our experiment setting, when the tumor volume reached approximately 120 mm3, 
the nude mice were randomly allocated into six groups (8 mice per group) before the 
experiments (day 0). For the treatment group (Ru2@AuNPs + laser), after the injection 
of the Ru2@AuNPs (200 g/20 g body weight), the HeLa tumors were irradiated with a 
diode laser (808 nm) at 0.8 W/cm2 for 5 min. We observed that the HeLa tumors were 
effectively ablated and round. Black scars were observed in the original sites, and the 
tumors were shrinking gradually or even disappeared individually after 10 days of 
treatment (Fig. 8). However, for the other five control groups of mice which were treated 
with 1) the Ru2@AuNPs alone; 2) a physiological saline solution followed by laser 
irradiation; 3) a physiological saline solution alone; 4) the AuNPs followed by laser 
irradiation; 5) Ru2 followed by laser irradiation, the tumors in these groups still grew 
quickly (Fig. S20 and Fig. S21). Histological examination was performed after the 
photothermal therapy treatment. As expected, in the mice treated with the Ru2@AuNPs 
followed by laser irradiation, the tumor tissues were necrotic, exhibiting pyknosis, 
karyolysis, and degradation. On the contrary, the tumor tissues of the four other mouse 
groups exhibited a normal-organised cellular structure (Fig. S20b). 
To determine whether the treatments induced toxicity, we monitored the body weight 
of the mice (Fig. S22) and the histology of organs including the liver, kidney, spleen, 
heart, lung, brain, intestine and ovary (Fig. S23). The the body weight of the mice treated 
with the Ru2@AuNPs under a diode laser (808 nm) irradiation at the power density of 
0.8 W/cm2 (group 2) was no different to that of the controls. No body weight loss and 
other serious toxic effects were observed. In addition, histological analysis did not reveal 
any serious irreversible pathological alterations or injuries in the organs of mice of all 
five groups. This strongly suggests that the Ru2@AuNPs medicated photothermal 
ablation is not inducing any toxicity. All results clearly indicate that the Ru2@AuNPs act 
as powerful photothermal agents in vivo. 
 
4. Conclusion 
In summary, in this article, we present a successful strategy for efficiently improving 
the photothermal therapy efficiency of gold nanospheres by grafting two-photon 
luminescent Ru(II) complex antennas. The best dual functional nanoparticles, namely the 
Ru2@AuNPs, exhibited both strong two-photon luminescence and high photothermal 
therapy efficiency (ΔT = 38.5 C,  = 33.3%). The Ru2@AuNPs were used for 
two-photon luminescent imaging-guided PTT in real time in living cells. Very 
importantly, the photothermal therapy potential of the Ru2@AuNPs was further 
demonstrated on mice. These in vivo experiments indicated that the use of Ru2@AuNPs 
as PTT agents offer excellent tumor ablation therapeutic efficacy under a diode laser (808 
nm) irradiation at the power density of 0.8 W/cm2 for 5 min. The laser power used in the 
present study was even lower than those of some recent reports[58-64]. All in all, our 
study highlights the potential of using Ru(II)-functionalized AuNPs for cancer 
theranostic applications. 
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Scheme and Figure Captions 
Table 1 Summary of the characteristics of the AuNPs and of the Ru@AuNPs. 
Fig. 1 Schematic illustration of the three different Ru(II) complexes (Ru1, 
Ru2, Ru3) grafted onto gold nanoparticles (Ru1@AuNPs, 
Ru2@AuNPs, Ru3@AuNPs) of the change of two-photon 
luminescence and of the photothermal efficiency of the Ru@AuNPs. 
GM is the unit of two-photon absorption cross-section  (1 GM = 1  
10-50 cm4s-1photon-1). 
Fig. 2 (a, b) TEM and HRTEM images of the synthesized Ru2@AuNPs 
(sample D, 50 g/mL). (c) EDX spectrum of the Ru2@AuNPs. (d) 
XPS spectra of the Ru2@AuNPs (C1s and Ru3d). 
Fig. 3 Two-photon absorption cross-section of the Ru(II) complexes and of 
the Ru@AuNPs obtained using excitation wavelengths from 700 to 
1050 nm. 
Fig. 4 a) Photothermal images of the gold nanoparticle solutions (sample D 
in Table 1) at the same concentration (100 L, 50 g/mL) and 
irradiation time (0-5 min). The power of the 808 nm laser was 0.8 
W/cm2 (A: Ru1@AuNPs; B: Ru2@AuNPs; C: Ru3@AuNPs; D: 
AuNPs; E: Ru1; F: Ru2; G: Ru3; H: H2O). b) The temperature change 
of the Ru@Au nanoparticles as a function of irradiation time; H2O and 
pure gold nanoparticles as controls. 
Fig. 5 UV-vis-NIR absorption spectra of the Ru2@AuNPs (a) and of the 
AuNRs (b) in the aqueous solution, and TEM images of the 
Ru2@AuNPs (c) and of the AuNRs ( d) morphology before and after 
808 nm laser irradiation (0.8 W/cm2, 30 min). 
Fig. 6 a) Cell viability of HeLa cancer cells after treatment with different 
concentration of the Ru2@AuNPs (45.01.5 nm size) for 24 h under 
no laser irradiation. b) Viability of HeLa cells after Ru2@AuNPs 
(45.01.5 nm size, 50 g/mL) induced photothermal therapy upon 808 
nm irradiation at different laser power densities. The Ru2 complex 
was included as a control. c) Real-time two-photon luminescence 
images of the Ru2@AuNPs (45.01.5 nm size, 50 g/mL) in HeLa 
cells measured by laser scanning confocal microscope after different 
irradiation times (808 nm, 0.8 W/cm2, 0-5 min). White circle indicates 
the laser spot. Membrane blebbing (green arrow) and apoptotic bodied 
(yellow arrow) were observed. 
Fig. 7 Cellular uptake analysis of the Ru2@AuNPs by a) flow cytometry b) 
ICP-MS; c) Confocal fluorescence microscopy (from left to right: 
bright field, Ru@AuNPs’ two-photon luminescence, Hoechst 33258 
luminescence and overlay images); d) TEM images show that the 
Ru2@AuNPs form an endosome (white ) after entering the cell; 
HeLa cells incubated with the Ru2@AuNPs (50 g/mL) at 37 ºC for 1 
h. 
Fig. 8 a) Representative photographs of HeLa tumors in mice in the presence 
of the Ru2@AuNPs without/with 808 nm laser treatments (0.8 W/cm2, 
5 min). b) Histological examination of tumors without/with laser 
treatments on day 10. c) The tumor growth curves for the two mice 
groups after treatment. The dose was 200 g nanoparticles per 20 g 
mouse body weight. Tumor volumes were normalized to their initial 
sizes. Error bars represent the standard deviation of 8 mice per group. 
* = p < 0.01, compared with the Ru2@AuNPs group. 
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Table 1 
Summary of the characteristics of the AuNPs and of the Ru@AuNPs. 
Ru@AuNPs Size/nm N(Ru)/AuNPs
Zeta potential 
(mV) 
Luminescence 
quenching 
TPA (/GM) 
at 808 nm 
T/C  
Ru1@AuNPs  A 4.00.3 112 +11.9 80.5% 18.0 22.4 19.2%
B 13.01.0 336 +16.6 92.3% 12.0 26.7 21.7%
C 32.01.5 470 +20.7 94.7% 9.9 29.9 23.8%
D 42.02.0 523 +23.9 96.5% 7.8 32.4 25.9%
Ru2@AuNPs A 5.40.5 180 +15.6 22.6% 308 23.7 19.9%
B 14.00.7 507 +21.8 40.8% 241 30.2 25.5%
C 34.01.5 715 +24.9 55.2% 209 35.4 31.4%
D 45.01.5 810 +26.4 57.9% 187 38.5 33.3%
Ru3@AuNPs A 5.20.5 205 +16.0 12.7% 154 19.4 18.3%
B 16.01.0 624 +22.2 33.6% 123 21.7 19.1%
C 35.00.8 843 +26.2 38.8% 110 26.5 21.6%
D 47.02.0 890 +27.0 40.5% 105 29.1 23.5%
AuNPs A 3.50.2  -26.6    8.6   7.3%
B 10.00.5  -26.8   9.4   8.5%
C 27.01.0  -27.6   11.3   9.6%
D 40.01.5  -28.5   12.1 10.2%
 
 Fig. 1. Schematic illustration of the three different Ru(II) complexes (Ru1, Ru2, Ru3) 
grafted onto gold nanoparticles (Ru1@AuNPs, Ru2@AuNPs, Ru3@AuNPs) of the 
change of two-photon luminescence and of the photothermal efficiency of the 
Ru@AuNPs. GM is the unit of two-photon absorption cross-section  (1 GM = 1  10-50 
cm4s-1photon-1). 
 Fig. 2. (a, b) TEM and HRTEM images of the synthesized Ru2@AuNPs (sample D, 50 
g/mL). (c) EDX spectrum of the Ru2@AuNPs. (d) XPS spectra of the Ru2@AuNPs 
(C1s and Ru3d).  
 Fig. 3. Two-photon absorption cross-section of the Ru(II) complexes and of the 
Ru@AuNPs obtained using excitation wavelengths from 700 to 1050 nm.  
 
 
 
 
 
 
 
 
 Fig. 4. a) Photothermal images of the gold nanoparticle solutions (sample D in Table 1) 
at the same concentration (100 L, 50 g/mL) and irradiation time (0-5 min). The power 
of the 808 nm laser was 0.8 W/cm2 (A: Ru1@AuNPs; B: Ru2@AuNPs; C: 
Ru3@AuNPs; D: AuNPs; E: Ru1; F: Ru2; G: Ru3; H: H2O). b) The temperature change 
of the Ru@Au nanoparticles as a function of irradiation time; H2O and pure gold 
nanoparticles as controls. 
  
 Fig. 5. UV-vis-NIR absorption spectra of the Ru2@AuNPs (a) and of the AuNRs (b) in 
the aqueous solution, and TEM images of the Ru2@AuNPs (c) and of the AuNRs ( d) 
morphology before and after 808 nm laser irradiation (0.8 W/cm2, 30 min). 
 Fig. 6. a) Cell viability of HeLa cancer cells after treatment with different concentration 
of the Ru2@AuNPs (45.01.5 nm size) for 24 h under no laser irradiation. b) Viability of 
HeLa cells after Ru2@AuNPs (45.01.5 nm size, 50 g/mL) induced photothermal 
therapy upon 808 nm irradiation at different laser power densities. The Ru2 complex was 
included as a control. c) Real-time two-photon luminescence images of the Ru2@AuNPs 
(45.01.5 nm size, 50 g/mL) in HeLa cells measured by laser scanning confocal 
microscope after different irradiation times (808 nm, 0.8 W/cm2, 0-5 min). White circle 
indicates the laser spot. Membrane blebbing (green arrow) and apoptotic bodied (yellow 
arrow) were observed. 
 
 Fig. 7. Cellular uptake analysis of the Ru2@AuNPs by a) flow cytometry b) ICP-MS; c) 
Confocal fluorescence microscopy (from left to right: bright field, Ru@AuNPs’ 
two-photon luminescence, Hoechst 33258 luminescence and overlay images); d) TEM 
images show that the Ru2@AuNPs form an endosome (white ) after entering the cell; 
HeLa cells incubated with the Ru2@AuNPs (50 g/mL) at 37 ºC for 1 h. 
 Fig. 8. a) Representative photographs of HeLa tumors in mice in the presence of the 
Ru2@AuNPs without/with 808 nm laser treatments (0.8 W/cm2, 5 min). b) Histological 
examination of tumors without/with laser treatments on day 10. c) The tumor growth 
curves for the two mice groups after treatment. The dose was 200 g nanoparticles per 
20 g mouse body weight. Tumor volumes were normalized to their initial sizes. Error 
bars represent the standard deviation of 8 mice per group. * = p < 0.01, compared with 
the Ru2@AuNPs group. 
 
